Market Research Logo

Global Alzheimer's Drugs Market 2017-2021

About Alzheimer's Drugs

Alzheimer's disease is a progressive and irreversible degeneration of the brain that disrupts the thinking, language, behavior, and cognitive skills of a person. It is more prevalent in people aged 65 years and above and affects more women than men. As per the Centers for Disease Control and Prevention (CDC), 5.4 million Americans are affected by this disease, and the incidence rate of disease increases with age and doubles every five years for adults beyond 65 years of age.

Technavio’s analysts forecast the global alzheimer's drugs market to grow at a CAGR of 1.90% during the period 2017-2021.

Covered in this report

The report covers the present scenario and the growth prospects of the global alzheimer's drugs market for 2017-2021. To calculate the market size, the report considers the sales of branded, generic, and off-label drugs.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA
Technavio's report, Global Alzheimer's Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • ALLERGAN
  • Eisai Pharmaceuticals
  • Johnson & Johnson
  • Novartis
Other prominent vendors
  • Amgen
  • Pfizer
Market driver
  • Appropriate strategies designed to increase public awareness
  • For a full, detailed list, view our report
Market challenge
  • Social stigma associated with Alzheimer's disease
  • For a full, detailed list, view our report
Market trend
  • Reformulation of marketed drugs
  • For a full, detailed list, view our report
Key questions answered in this report
  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?


Press Release

Technavio Announces the Publication of its Research Report – Global Alzheimer's Drugs Market 2017-2021

Technavio recognizes the following companies as the key players in the global alzheimer's drugs market: ALLERGAN, Eisai Pharmaceuticals, Johnson & Johnson, and Novartis.

Other Prominent Vendors in the market are: Amgen, and Pfizer.

Commenting on the report, an analyst from Technavio’s team said: “One trend in the market is reformulation of marketed drugs. The global Alzheimer’s drugs market is currently witnessing an increasing trend of reformulation of already market drugs to increase patient adherence to the treatment. Drug delivery systems such as transdermal patches, ER formulations, and orally disintegrating tablets increase the efficacy of drugs either by increasing the patient compliance or by increasing the bioavailability of a drug.”

According to the report, one driver in the market is appropriate strategies designed to increase public awareness. Although the risk of developing Alzheimer's disease increases exponentially with age, the CDC estimates that approximately 220,000-640,000 Americans under the age of 65 years are suffering from dementia, particularly Alzheimer's disease. The early onset of symptoms of Alzheimer's disease is often called as younger-onset. However, the diagnosis of individuals with younger-onset is delayed by several months or years as these symptoms are often attributed to external factors such as head injury, improper sleep, trauma or tragedy that had occurred in the past, stress conditions, and improper diagnosis of disease.

Further, the report states that one challenge in the market is social stigma associated with Alzheimer's disease. Alzheimer's disease is perceived in different ways in different parts of the world, ranging from a component of aging to a supernatural event. This, in turn, has a negative impact on those suffering from dementia as they often refrain from reporting their symptoms to healthcare providers, leading to low diagnostic rates, thus hampering the market growth. In some parts of the world, public disclosure of such symptoms triggers negative reactions from family and friends leading to quarantine in some cases.



Companies Mentioned

ALLERGAN, Eisai Pharmaceuticals, Johnson & Johnson, and Novartis.Amgen, and Pfizer.

  • Executive summary
  • Scope of the report
  • Research Methodology
  • Introduction
    • Market outline
  • Alzheimer's disease: An overview
    • Table Alzheimer disease: A brief overview
    • Table Progression of Alzheimer's disease
    • Table Mechanism of pathogenesis of Alzheimer's disease
    • Table Risk factors responsible for development of Alzheimer's disease
    • Table Alzheimer's disease treatment: Milestones
    • National Alzheimer's Project
      • Table Vendor's initiative for promoting Alzheimer's drugs business
  • Market landscape
    • Market overview
      • Table Global Alzheimer's drugs market: Snapshot
    • Market size and forecast
      • Table Global Alzheimer's drugs market 2016-2021 ($ millions)
      • Table Opportunity analysis of global Alzheimer's drugs market
    • Five forces analysis
      • Table Five forces analysis
  • Pipeline landscape
    • Table Pipeline snapshot based on number of molecules
    • Table Key clinical trials
    • Table Alzheimer's drugs with fast track designation
  • Market segmentation by MoA
    • Table Market segmentation based on MoA
    • Table Global Alzheimer's drugs market share based on MoA
    • AChE inhibitors
      • Table Global Alzheimer's AChE inhibitors drugs market 2016-2021 ($ millions)
    • Glutamate inhibitors
      • Table Global Alzheimer's glutamate inhibitors drugs market 2016-2021 ($ millions)
  • Market assessment of FDA-approved drugs
    • Table FDA-approved drugs for the treatment of Alzheimer's disease
    • Aricept
      • Table Key events timeline for Aricept formulations in Japan
      • Table Key events timeline for Aricept in US and Europe
    • Exelon
      • Table Exelon revenue 2015 and 2016 ($ millions)
      • Table Key events timeline for Exelon formulation
    • NAMENDA
      • Table NAMENDA revenue 2015 and 2016 ($ millions)
      • Table Key events timeline for NAMENDA
    • Razadyne
      • Table Razadyne revenue 2015 and 2016 ($ millions)
      • Table Key events timeline for Razadyne
  • Geographical segmentation
    • Table Global Alzheimer's drugs market share by geography 2016 and 2021
    • Table Global Alzheimer's drugs market revenue by geography 2016-2021
    • Table Alzheimer's drugs market scenario in different geographies
    • Alzheimer's drugs market in Americas
      • Table Market scenario in Americas
      • Table Alzheimer's drugs market in Americas 2016-2021 ($ millions)
    • Alzheimer's drugs market in EMEA
      • Table Market scenario in EMEA
      • Table Alzheimer's drugs market in EMEA 2016-2021 ($ millions)
    • Alzheimer's drugs market in APAC
      • Table Market scenario in APAC
      • Table Alzheimer's drugs market revenue in APAC 2016-2021 ($ millions)
  • Decision framework
  • Drivers and challenges
    • Market drivers
      • Table Death rate per 100,000 of US population due to Alzheimer's disease 2010-2014
    • Market challenges
      • Table Revenue erosion of Aricept after loss of exclusivity
  • Market trends
    • Rising government initiatives to support Alzheimer's disease
    • Rising burden of Alzheimer's disease
      • Table Estimated number of people aged 65 and older with Alzheimer's disease in the US, 2010-2050
    • Reformulation of marketed drugs
  • Vendor landscape
    • Competitive scenario
      • Table Competitive structure analysis of global Alzheimer's drugs market 2016
  • Key vendor analysis
    • ALLERGAN
      • Table ALLERGAN: Key highlights
      • Table ALLERGAN: Strength assessment
      • Table ALLERGAN: Strategy assessment
      • Table ALLERGAN: Opportunity assessment
    • Eisai Pharmaceuticals
      • Table Eisai Pharmaceuticals: key highlights
      • Table Eisai Pharmaceuticals: Strength assessment
      • Table Eisai Pharmaceuticals: Strategy assessment
      • Table Eisai Pharmaceuticals: Opportunity assessment
    • Johnson & Johnson
      • Table Johnson & Johnson: Key highlights
      • Table Johnson & Johnson: Strength assessment
      • Table Johnson & Johnson: Strategy assessment
      • Table Johnson & Johnson: Opportunity assessment
    • Novartis
      • Table Novartis: Key highlights
      • Table Novartis: Strength assessment
      • Table Novartis: Strategy assessment
      • Table Novartis: Opportunity assessment
    • Other prominent vendors
  • Appendix
    • List of abbreviations
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report